Abstract
The mutant form of human apoA1, known as apoA1 Milano, is formed as a result of arginine 173 to cysteine substitution and inhibits experimental atherosclerosis in cholesterol-fed animals. This study was designed to determine if apoA1 Milano would modify arterial thrombogenesis. Sprague Dawley rats were intravenously administered the carrier alone (n=8) or apoA1 Milano (20 mg · kg-1 · d-1 for 4 to 10 days, n=17). The abdominal cavity was opened, and the abdominal aorta was isolated. Whatman paper impregnated with 35% FeCl3 was wrapped around the surface of the aorta, and aortic flow was recorded continuously. In carrier-treated rats, an occlusive platelet-fibrin-rich thrombus was formed in 21.2±4.1 (mean±SD) minutes. Treatment of rats with apoA1 Milano markedly delayed time to thrombus formation (38.8±11.9 versus 21.2±4.1 minutes, P
Original language | English (US) |
---|---|
Pages (from-to) | 378-383 |
Number of pages | 6 |
Journal | Arteriosclerosis, Thrombosis, and Vascular Biology |
Volume | 19 |
Issue number | 2 |
State | Published - 1999 |
Externally published | Yes |
Keywords
- ApoA1
- Apolipoproteins
- Lipoproteins, HDL
- Thrombosis
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine